RxDoctor Payments Data

Donald Weese, MD

Urology · Burley, IDNPI 1154323392

Payments from drug & device makers

What this record shows

This record is dominated by education: $1,775 of the $2,401 with a category attached, or 73.9%. Intuitive Surgical accounts for 62.5% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $1,500, 5.0 times the $303 reported in 2019. That places this record below the midpoint for urology clinicians in ID, where the typical reported total is $3,075.

$2,401in general payments, 2019–2025

Across 41 payments — averaging $58.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Astellas Pharma US Inc$402
  • Coloplast$130
  • Myovant Sciences Inc.$69
  • AbbVie$63
  • Sumitomo Pharma America, Inc.$48
  • plus $189 from 9 others

What the payments were for

  • Food & beverage$62726%
  • Education$1,77574%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,401 in reported general payments places this provider in the 30th percentile of 55 urology providers in Idaho.

See all urology providers in Idaho

Medicare billing

Part B allowed, 2024
$155,042
Medicare patients
450
Services billed
2,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol200$12,133
MyrbetriqMirabegron20$10,685
Tamsulosin Hcl224$4,053
Oxybutynin Chloride ErOxybutynin Chloride183$3,694
Finasteride138$2,283
Trospium Chloride27$2,070
Alfuzosin Hcl ErAlfuzosin Hcl37$1,940
Potassium Citrate ErPotassium Citrate11$1,915
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst48$1,666
Trimethoprim12$1,355
NitrofurantoinNitrofurantoin Macrocrystal12$1,023
Ciprofloxacin Hcl39$510
Solifenacin Succinate12$479
Testosterone Cypionate14$472
Cefdinir25$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$402$10,68520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 55 urology providers in Idaho.

Other urology in Burley

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →